Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

  • This share is currently suspended. It was suspended at a price of 5.375

Share Price Information for Iconic Labs (ICON)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.375
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.375
ICON Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Charity Commitment

12 Jul 2017 07:00

RNS Number : 7820K
WideCells Group PLC
12 July 2017
 

12 July 2017

WideCells Group PLC ('WideCells Group' or 'the Group')

Corporate Charity Commitment

 

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is delighted to announce that it has finalised a corporate charity engagement plan as part of its active corporate social responsibility programme. Reflecting his commitment to promoting medical development and health and well-being at both a corporate and personal level, the Group's Chief Executive Office ('CEO') João Andrade has commenced training to participate in a 135 mile ultramarathon in the Californian desert in order to raise money for three primary charities: BigMoose, a non-profit organisation which aims to tackle homelessness by training homeless people as baristas, the Portuguese Association Multiple Sclerosis ('SPEM' - the Sociedade Portuguesa de Esclerose Múltipla) and CHAMPS Appeal, which helps children with Hirschsprung's Disease and bowel/bladder diversions.

 

A blog post covering Mr. Andrade's training and the Company's charitable commitments can be found here: http://widecellsgroup.com/newsroom/blog

 

The Challenge

 

WideCells Group hopes to raise £50,000 in the first year of its charity commitment programme to support three charities.

 

The achieve this, the Group is finalising a comprehensive sponsorship package and CEO João Andrade has commenced training so that he can participate in an ultramarathon often referred to as "The World's Toughest Foot Race", covering 135 miles. The start line is at Badwater, Death Valley, California, which marks the lowest elevation in North America at 85m below sea level, and finishes at Whitney Portal, which is the trailhead to the Mt. Whitney summit, the highest point in the contiguous United States, at 2,530m above sea level. The Badwater 135 course covers three mountain ranges for a total of 4,450m of cumulative vertical ascent and 1,859m of cumulative descent.

 

Application to the race is, and always has been, by invitation only. Applicants must meet a number of qualifying standards, including the completion of at least three running races of at least 100 continuous miles in length, at least one of which must be completed within 12 months of running Badwater. Accordingly, Mr. Andrade hopes to be in a position to participate in the race in 2020.

 

The Charities

 

BigMoose

BigMoose, is a non-profit organisation with a very clear intention - to do fun stuff that inspires people to live better, healthier, kinder lives. The charity organises multiple fundraising and charity events to support a spectrum of causes and is currently focussed on tackling homelessness in Cardiff, Wales. They intend to do this through a Big Moose café, which has been founded in Cardiff to train people who are currently homeless as baristas, so that they have the skills and support to start a new life. For further information please visit: www.bigmoose.co

 

SPEM - the Portuguese Association Multiple Sclerosis

SPEM is focussed on improving the living conditions of Multiple Sclerosis patients and the people who live with them. MS is a chronic inflammatory and degenerative disease affecting the Central Nervous System (CNS). It is a disease that often occurs between 20 and 40 years of age and currently affects an estimated 2,500,000 people around the world, with more than 8,000 in Portugal alone. The charity is based in Lisbon, Portugal and has a close affinity with the Group's operations given that stem cells are currently being used in clinical trials to treat MS. Furthermore, the Group's CellPlan Limited division, which recently launched a first-of-its-kind stem cell healthcare insurance plan in the UK, is based in Porto, Lisbon. For further information please visit: www.spem.pt

 

CHAMPS Appeal

CHAMPS Appeal helps children with Hirschsprung's Disease and bowel/bladder diversions. They give solace to children by providing activities with other children like them, whilst parents/carers get the opportunity to relax and discuss their family's journey with like-minded families. For further information please visit: www.champsappeal.co.uk

 

 

WideCells Group CEO, João Andrade, said, "WideCells Group is committed to supporting future medical development to ensure a brighter future for healthcare globally. We have already proven this through our work to make stem cell treatment more accessible and affordable worldwide, which resulted in us being ranked as the 21st most disruptive company globally by DISRUPT 100. Nonetheless, as our shareholders will know, we are committed to driving and supporting change at all levels. Accordingly, we are delighted to be working with and supporting a number of very worthy charities as part of our Corporate Social Engagement plan. These charities have already positively benefitted thousands of lives and we want to help them to continue their incredible work. That is why I have personally undertaken the challenge to run the Badwater ultramarathon. I am passionate about transforming the future medical landscape both within my capacity as CEO of WideCells Group and personally. Now is this time for change and we look forward to being at the fore of this."

 

**ENDS**

 

For further information, please visit the Company's website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

 

WideCells Group

CEO - João Andrade

Tel: +351 919 033 171

Smaller Company Capital Ltd

Broker - Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker - Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR - Charlotte Page & Olivia Vita

Tel: +44 (0) 20 7236 1177

 

Notes to Editors

 

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. In June 2017, the Group was ranked as the 21st most disruptive company globally by DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets.

 

With this in mind, it has created three divisions:

· CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process

· WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

· WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

 

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

 

Stem Cell Fast Facts:

· Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of this.

· Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells

· 82 illnesses can currently be treated using stem cell procedures

· Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGMNMMMGNZZ
Date   Source Headline
28th Mar 20247:00 amRNSInterim Results
11th Mar 202412:00 pmRNSHeads of Terms Signed
29th Feb 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSSuspension of Trading
13th Feb 20242:08 pmRNSResult of AGM
7th Feb 20249:10 amRNSConversion of Notes and Allotment of Shares
19th Jan 20243:49 pmRNSNotice of AGM
4th Jan 20247:00 amRNSBoard Changes & Business and Strategy Update
29th Dec 20237:00 amRNSTotal Voting Rights
7th Dec 20238:53 amRNSConversion of Securities
4th Dec 20237:53 amRNSConversion of Securities
30th Nov 20237:00 amRNSTotal Voting Rights
17th Nov 202311:32 amRNSConversion of Securities
13th Nov 20238:40 amRNSConversion of Securities
2nd Nov 202310:35 amRNSConversion of Securities
31st Oct 20239:29 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSFull Year Results for the Year ended 30 June 2023
24th Oct 20235:31 pmRNSChange of Auditor
17th Oct 20237:51 amRNSConversion of Securities
13th Oct 202311:32 amRNSAnnouncement of the Completion of CVA
13th Oct 202311:30 amRNSConversion of Securities
29th Sep 20238:01 amRNSTotal Voting Rights
22nd Sep 20239:40 amRNSConversion of Securities
18th Sep 20236:27 pmRNSConversion of Notes – Replacement
18th Sep 20237:37 amRNSConversion of Securities
12th Sep 20238:45 amRNSStatement re CVA
4th Sep 202312:02 pmRNSConversion of Securities
31st Aug 20237:21 amRNSTotal Voting Rights
25th Aug 20234:49 pmRNSResult of AGM
18th Aug 20237:51 amRNSConversion of Securities
14th Aug 20237:59 amRNSIssue of Debt
8th Aug 20232:58 pmRNSPublication of a Prospectus
4th Aug 20234:19 pmRNSNotice of AGM
30th Jun 20239:12 amRNSTotal Voting Rights
2nd Jun 20231:20 pmRNSIssue of Equity
28th Apr 202310:35 amRNSTotal Voting Rights
12th Apr 20238:13 amRNSConversion of Securities
31st Mar 20233:11 pmRNSTotal Voting Rights
31st Mar 20231:59 pmRNSHalf-year Report
29th Mar 20232:05 pmRNSSecond Price Monitoring Extn
29th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Mar 20237:42 amRNSConversion of Securities
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 202311:48 amRNSSubscription of Convertible Notes
21st Mar 202311:05 amRNSSecond Price Monitoring Extn
21st Mar 202311:00 amRNSPrice Monitoring Extension
21st Mar 20239:05 amRNSSecond Price Monitoring Extn
21st Mar 20239:00 amRNSPrice Monitoring Extension
20th Mar 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.